Effectiveness and Safety of Risperidone and Aripiprazole in Treating Autism Spectrum Disorder: A Narrative Review
DOI:
https://doi.org/10.11606/issn.1679-9836.v104i1e-227101Keywords:
Autism Spectrum Disorder, Risperidone, Aripiprazole, Efficacy, Side EffectAbstract
The article evaluates the effectiveness, safety, and effects of two medications (risperidone and aripiprazole) in controlling symptoms associated with Autism Spectrum Disorder (ASD). ASD is characterized by difficulties in social communication and repetitive behaviors, with varied manifestations among individuals. Early diagnosis is crucial for implementing effective interventions that improve the quality of life of those affected. The research consists of a narrative literature review, using databases such as Medline, LILACS, PubMed, and Google Scholar to analyze pharmacological treatment of ASD with risperidone and aripiprazole. The search strategy focused on recent studies (2019-2024) in Portuguese. Four relevant studies were selected that investigated the efficacy and safety of these medications. Risperidone was found to be effective in controlling aggression and irritability but is associated with side effects such as weight gain and drowsiness. In contrast, aripiprazole, with a potentially more favorable side effect profile, demonstrated significant efficacy in reducing behavioral symptoms, although it also presents challenges such as digestive problems and weight gain. It is concluded that both medications offer benefits in treating ASD, but the choice between them should consider not only clinical efficacy but also individual tolerability and the need for monitoring adverse effects throughout treatment.
Downloads
References
Evangelho VGO, Fernandes JS, Lopes A, Lima ML, Silva R. Autismo no Brasil: uma revisão sobre estudos em neurogenética. Rev Neurociênc. 2021;29:1-20. Doi: 10.34024/rnc.2021.v29.12440.
Viana ACV, Souza PL, Martins R, Oliveira L, Rocha D. Autismo: uma revisão integrativa. Saúde Dinâmica. 2020;2(3):1-18. Doi: 10.4322/2675-133X.2022.017.
Costa GON, de Carvalho Abreu CR. Os benefícios do uso de psicofármacos no tratamento de indivíduos com transtorno do espectro autista (TEA): revisão bibliográfica. Rev JRG Estud Acadêmicos. 2021;4(8):240-51. Doi: 10.5281/zenodo.4637757.
Lopes AMCS. O autismo e suas conexões: qual medicação para o autista? Psicol Rev. 2019;25(3):1343-52. Doi: 10.5752/P.1677-1168.2019v25n3p1343-1352.
Ministério da Saúde (BR). Protocolo clínico e diretrizes terapêuticas do comportamento agressivo no transtorno do espectro do autismo [Internet]. Brasília (DF): Ministério da Saúde; 2022 [atualizado em 13 jul. 2023; citado em 21 jan. 2025]. Disponível em: https://www.gov.br/conitec/pt-br/midias/protocolos/20220419_portal-portaria_conjunta_7_comportamento_agressivo_tea.pdf/view?utm_source=chatgpt.com
Neves KRT, Silveira ST, Araújo JRL, Lopes FCB. Segurança da risperidona em crianças e adolescentes com transtorno do espectro autista. Infarma-Ciências Farm. 2021;33(2):138-48. Doi: 10.14450/2318-9312.v33.e2.a2021.pp138-148.
Guedes PAMN, Souza RS, Lima PF, Santos TL, Oliveira DA. Efeitos positivos e negativos da análise do comportamento aplicada e risperidona em crianças portadoras de autismo. Rev Foco. 2023;16(7). Doi: 10.54751/revistafoco.v16n7-132.
Blanco LERM, Tavares LEA, Pereira D. O uso de Aripiprazol no tratamento do Transtorno do Espectro Autista: uma Revisão Integrativa de Literatura. Saúde Única: Uma Jornada Colaborativa para a Promoção da Saúde Humana, Animal e Ambiental. p. 11. Doi: 10.5281/zenodo.10716840.
Cadide AC, Freitas WM, Sabec-Pereira DK. Perfil medicamentoso da Risperidona em pacientes com transtorno do espectro autista (TEA). Rev JRG Estud Acad. 2024;7(14). Doi: 10.55892/jrg.v7i14.1272.
Fanti LM, COSTA AMN. Aripiprazol: o mais novo antipsicótico de nova geração. Psiquiatr Biol. 2003;10(1):15-21.
Caetano D. Risperidona: um novo antipsicótico atípico: revisão da farmacocinética e da farmacodinâmica. J Bras Psiquiatr. 1995;44(6):305-310.
McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002;347(5):314-21. Doi: 10.1056/NEJMoa013171.
Bartram LA, Lozano J, Coury DL. Aripiprazole for treating irritability associated with autism spectrum disorders. Expert Opin Pharmacother. 2019;20(12):1421-7. Doi: 10.1080/14656566.2019.1626825.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Gabriel Cabriny Doutor, Hudson Rosa da Silva Leão Filho, Thiago Silvestre Boscath Santos, Vitória Roberta Andrade Silva, Larissa Lima Nascimento, Luiz Cláudio Kehdi Guimarães, Isadora Engel Marques, Fernanda Oliveira da Costa Caetano, Vitória Faria Bertoloni, Giovanna Ribeiro
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
